These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24050284)

  • 1. Mycobacterium poriferae infection in a psoriasis patient on anti-TNF-α therapy.
    Laquer V; Ta T; Nguyen T; Tan B
    Dermatol Online J; 2013 Sep; 19(9):19609. PubMed ID: 24050284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive cutaneous infection with Mycobacterium marinum in two patients receiving anti-tumor necrosis factor-alfa agents.
    Caron J; Michot C; Fabre S; Godreuil S; Guillot B; Dereure O
    J Am Acad Dermatol; 2011 Nov; 65(5):1060-2. PubMed ID: 22000874
    [No Abstract]   [Full Text] [Related]  

  • 5. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept.
    Vine K; Votava HJ; Smith BL
    Cutis; 2012 Sep; 90(3):132-6. PubMed ID: 23094312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
    Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
    Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy.
    van Ingen J; Boeree M; Janssen M; Ullmann E; de Lange W; de Haas P; Dekhuijzen R; van Soolingen D
    Nat Clin Pract Rheumatol; 2007 Jul; 3(7):414-9. PubMed ID: 17599076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy.
    Varley CD; Deodhar AA; Ehst BD; Bakke A; Blauvelt A; Vega R; Yamashita S; Winthrop KL
    Rheumatology (Oxford); 2014 Feb; 53(2):332-7. PubMed ID: 24173434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cutaneous infection due to Mycobacterium chelonae during anti-TNF therapy].
    Adenis-Lamarre E; Kostrzewa E; Texier-Maugein J; Doutre MS
    Ann Dermatol Venereol; 2009 Nov; 136(11):811-4. PubMed ID: 19917435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept in psoriasis treatment.
    Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
    Chiu HY; Hsueh PR; Tsai TF
    Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy.
    Cassano N; Coviello C; Loconsole F; Miracapillo A; Vena GA
    Eur J Dermatol; 2006; 16(3):316-7. PubMed ID: 16709508
    [No Abstract]   [Full Text] [Related]  

  • 17. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.